Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure

Area of Science:

• Hematology
• Oncology
• Nephrology

Background:

• Multiple myeloma is a plasma cell disorder with a poor prognosis.
• Renal insufficiency is a common and severe complication impacting multiple myeloma prognosis.
• Investigating safe and effective chemotherapy for myeloma patients with impaired kidney function is crucial.

Purpose of the Study:

• To evaluate the safety and efficacy of an intermediate dose of intravenous melphalan (25 mg/m2) in multiple myeloma patients with renal impairment.
• To determine survival rates, duration of response, and toxicity associated with this treatment regimen.
• To conduct a pharmacokinetic study of melphalan in patients with varying degrees of renal function.

Main Methods:

• A cohort of 45 multiple myeloma patients received a single intravenous dose of melphalan (25 mg/m2).
• Survival, response duration, and toxicity were analyzed.
• Melphalan pharmacokinetics were assessed in relation to renal function.

Main Results:

• Overall median survival was 45 months. 79% of patients had renal impairment.
• No significant difference in survival was observed for stage III patients with or without renal insufficiency.
• Despite a positive correlation between melphalan exposure and renal impairment, patients with severe renal dysfunction, including those on dialysis, did not experience increased leukopenia.

Conclusions:

• Renal impairment does not contraindicate aggressive chemotherapy for multiple myeloma.
• Intravenous melphalan at 25 mg/m2 demonstrates good survival and acceptable toxicity in patients with renal impairment.
• A randomized trial is warranted to compare this melphalan dose against standard treatments.